Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita - A systematic literature review

被引:56
作者
Kirtschig, G
Murrell, D
Wojnarowska, F
Khumalo, N
机构
[1] Vrije Univ Amsterdam, Acad Ziekenhuis, Dept Dermatol, NL-1007 MB Amsterdam, Netherlands
[2] Oxford Radcliffe Hosp, Dept Dermatol, Oxford, England
[3] Univ New S Wales, St George Hosp, Dept Dermatol, Sydney, NSW, Australia
[4] Groote Schuur Hosp, Dept Dermatol Observ, ZA-7925 Cape Town, South Africa
关键词
D O I
10.1001/archderm.138.3.380
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To identify and critically evaluate evidence from randomized controlled trials for the efficacy of treatments for mucous membrane pemphigoid (MMP)/ cicatricial pemphigoid (CP) and epidermolysis bullosa acquisita (EBA). Search Strategy: Review of MEDLINE from 1966 through March 2000, EMBASE from 1980 through C, March 2000, and the Cochrane Controlled Trials Register (February 28, 2001) to identify randomized controlled trials for the efficacy of treatments in MMP/CP and FBA. Selection Criteria: All randomized controlled trials of therapeutic interventions that included patients with MMP/CP or EBA confirmed by immunofluorescence study findings. All age groups were included. Results: We found 2 small randomized controlled trials of MMP/CP, both conducted in patients with severe eye involvement. We were not able to identify a randomized controlled trial of therapeutic interventions in EBA. Conclusions: There is evidence from 2 small trials that severe ocular CP responds best to treatment with cyclophosphamide, and mild to moderate disease seems effectively suppressed by treatment with dapsone. No treatment recommendations can be made for EBA because to our knowledge no randomized controlled trials are published. Even though systemic corticosteroids are regarded as the gold standard in the treatment of MMP/CP and EBA, there is poor evidence from the literature that they are the best treatment for these diseases.
引用
收藏
页码:380 / 384
页数:5
相关论文
共 50 条
[11]   Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid [J].
Donnenfeld, ED ;
Perry, HD ;
Wallerstein, A ;
Caronia, RM ;
Kanellopoulos, AJ ;
Sforza, PD ;
D'Aversa, G .
OPHTHALMOLOGY, 1999, 106 (01) :72-78
[12]  
Dragan L, 1999, CUTIS, V63, P181
[13]   Bullous pemphigoid and epidermolysis bullosa acquisita: Presentation, prognosis, and immunopathology in 11 children [J].
Edwards, S ;
Wakelin, SH ;
Wojnarowska, F ;
Marsden, RA ;
Kirtschig, G ;
Bhogal, B ;
Black, MM .
PEDIATRIC DERMATOLOGY, 1998, 15 (03) :184-190
[14]   ROLE OF CYCLOPHOSPHAMIDE AND HIGH-DOSE STEROID IN OCULAR CICATRICIAL PEMPHIGOID [J].
ELDER, MJ ;
LIGHTMAN, S ;
DART, JKG .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (03) :264-266
[15]   Sulphapyridine - A new agent for the treatment of ocular cicatricial pemphigoid [J].
Elder, MJ ;
Leonard, J ;
Dart, JKG .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1996, 80 (06) :549-552
[16]   DAPSONE THERAPY FOR THE ACUTE INFLAMMATORY PHASE OF OCULAR PEMPHIGOID [J].
FERN, AI ;
JAY, JL ;
YOUNG, H ;
MACKIE, R .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1992, 76 (06) :332-335
[17]  
Fine JD, 1990, MANAGEMENT BLISTERIN, P83
[18]  
Foster C S, 1986, Trans Am Ophthalmol Soc, V84, P527
[19]   Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid -: A preliminary study [J].
Foster, CS ;
Ahmed, AR .
OPHTHALMOLOGY, 1999, 106 (11) :2136-2143
[20]  
FOSTER CS, 1982, OPHTHALMOLOGY, V89, P340